Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for GeneReach Biotechnology Corp. (4171:TWSE), powered by AI.
GeneReach Biotechnology Corp. is currently trading at $17.40. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for GeneReach Biotechnology Corp. on Alpha Lenz.
View GeneReach Biotechnology Corp.'s valuation metrics on Alpha Lenz.
“GeneReach Biotechnology Corp.'s ROE is -16.9%. Explore profitability and growth together.”
Ask for details →GeneReach Biotechnology Corp. is a biotechnology company specializing in the development, manufacturing, and marketing of applied nucleic acid detection technologies. Its primary purpose is to provide advanced diagnostic solutions across a spectrum of industries, focusing on pathogen detection platforms that include automatic nucleic acid extraction systems, polymerase chain reaction (PCR) detection equipment, and a range of specialized reagents and consumables. The company serves diverse sectors such as aquaculture, agriculture, food safety, human and animal health—delivering products that support disease management, prevention, and research applications. GeneReach Biotechnology Corp. is recognized for ensuring quality standards, with manufacturing processes that comply with ISO 13485 and Good Manufacturing Practices. Since its founding in 2004, the company has played a significant role in enabling faster, reliable, and accessible molecular diagnostics, supporting both large-scale industry and smaller point-of-care environments. Its work not only advances health management in Taiwan but also contributes to global health innovation by offering OEM/ODM services, research collaborations, and technical solutions to its partners and clients worldwide.
“GeneReach Biotechnology Corp.'s ROE is -16.9%. Explore profitability and growth together.”
Ask for details →GeneReach Biotechnology Corp. (ticker: 4171) is a company listed on TWSE in the Healthcare sector (Biotechnology).
The current price is 17.4 with a P/E ratio of -x and P/B of -x.
ROE is -16.92% and operating margin is -37.34%. Annual revenue is $233M.